Age at diagnosis and treatment for prostate cancer (PC) in two distinct integrated health care systems
| Autor: | Arif Hussain, Anitha Nallu, Rezwan Islam, Crystal Jacobson, Mark A. Ritter, Deanna Cross, C. Daniel Mullins |
|---|---|
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 31:240-240 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2013.31.6_suppl.240 |
| Popis: | 240 Background: An older age at diagnosis may affect the stage at which PC is diagnosed as well as the treatment decisions made by the providers and/or the patients. Here we compare two geographically and ethnically distinct PC cohorts to determine whether age affects treatment decisions. Methods: Populations- Marshfield Clinic (MC): individuals were included in the cohort if they were diagnosed with PC between January, 2005 and December, 2010 and enrolled in a population based biorepository. Veterans Affairs (VA):– cohort included individuals diagnosed with PC between January, 2010 and December, 2010 within the Baltimore VA Medical Center (BVAMC). Retrospective chart review using electronic abstraction from the EMR was performed at each site. Statistical analysis was performed using the chi-square test for categorical variables or Fisher's exact test if the cell size was under 5. Results: Compared to the MC population, the VA population had a younger median age at diagnosis (63 vs. 68), more African American men (63% vs. 0.5%) and exhibited higher median PSA at diagnosis (7.92 vs 5.78 ng/dL). Seventy nine percent of VA and 87% of MCpatientswere stage 1 or 2 at diagnosis (p=0.03). Stage was not associated with older age (age >/= 75) in either population. Individuals in the VA system were more likely to receive radiation (48% vs. 16%) and less likely to receive surgery than the MC population (18% vs. 59%). There were also several similarities in treatment decisions amongst these different populations. For instance, individuals with an older age (>/= 75 vs. other age categories) at diagnosis were more likely to receive non-aggressive treatments such as hormonal therapy or no treatment (>67% vs. /= 75 were still more likely to receive less aggressive treatment at both MC and BVAMC (>29% versus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|